Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
about
Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionDaclizumab for relapsing remitting multiple sclerosisDaclizumab for relapsing remitting multiple sclerosisInterleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionSafety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvantHuman Circulating and Tissue-Resident CD56(bright) Natural Killer Cell PopulationsDistinct Migration and Contact Dynamics of Resting and IL-2-Activated Human Natural Killer Cells.Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2.Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibodyGM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease.Therapeutic activity of NK cells against tumors.Ontogeny and expansion of human natural killer cells: clinical implications.IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells.IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function.CpG methylation changes within the IL2RA promoter in type 1 diabetes of childhood onset.Natural killer cell cytokine response to M. bovis BCG Is associated with inhibited proliferation, increased apoptosis and ultimate depletion of NKp44(+)CD56(bright) cells.Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation.High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibodyDecreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals.Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.Mucosal adjuvant activity of IL-2 presenting spores of bacillus subtilis in a murine model of Helicobacter pylori vaccination.Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.Determination of natural killer cell function by flow cytometry.Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2.Application of IL-2 and other cytokines in renal cancer.Human NK Cell Up-regulation of CD69, HLA-DR, Interferon γ Secretion and Cytotoxic Activity by Plasmacytoid Dendritic Cells is Regulated through Overlapping but Different Pathways.Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1.Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cellsLysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D.The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation.Expression of a functional c-kit receptor on a subset of natural killer cellsInterleukin 2 receptor gamma chain expression on resting and activated lymphoid cellsInterleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
P2860
Q24187927-D280DA92-5E14-4D19-BF3E-A4C6630EB7C2Q24200496-A20A56B8-E7D9-4206-B5EF-426A417E932CQ24201637-0726079F-78D9-43F0-B8A3-AEEA52ACDD81Q24202630-4FABF068-1B9D-4ABC-AC72-6C7916225622Q24655036-CF88DCE9-3E06-4D76-85C1-2D7E29B5CBF9Q26742158-B929A1C0-7148-436E-B8B1-2398D0D5E305Q30441681-4BE81946-78F2-4088-8E67-7FD8DF8DF478Q33380148-97365DD6-9B1E-49C6-8902-6C14A052F0BFQ33590557-95B2BDBC-A06A-4361-877E-142542D2669EQ33772422-E44551DB-0047-4C1B-8A36-8B9196DC440AQ34069811-CBCB9465-C491-4A49-828E-627E486C28D2Q34132358-73777367-2EBB-4FA8-9429-60074C5EF4A1Q34361383-94029C3A-0FAE-4EDB-90A5-C2BF871A7837Q34510446-DA9B5D76-D87A-4643-BB58-979A005A6152Q34552162-B2A8774F-E847-4341-AD8E-0A51E603FACCQ34552167-9A7F34F3-7622-4A5F-9F65-F2864ED8F964Q34651540-7E42BA9C-AB19-4301-B6D8-C55887522EBDQ34755351-EFEEB2E2-53CE-4273-96C6-B49D3833A99CQ34846677-1C89458C-6C62-4510-B930-D24A7AA2BC64Q34851503-0A5C526B-DB20-4BF4-8FD6-DBF05DC970A0Q34861084-3436FD2B-A71B-4CDF-8974-1CBB033A1664Q35013603-E91303CC-53BE-4877-AE91-1FB3C07EA6BBQ35037803-9A3CD40C-F95F-4F3C-9769-5FF0E33A0308Q35083850-B10F6018-BD55-4120-9601-70C2720F5CDFQ35127929-628CE8A4-B556-4DE0-AF9D-F460159343D8Q35152187-2D9F7E31-6262-47BE-8F02-5831DABF6C23Q35221140-59AF29EF-C254-4CDC-B279-F2D72A60EF36Q35226752-2BFCC291-ED8A-4247-825D-841C68E1AD18Q35573406-0F50BC2D-93CC-4438-A5FF-D4558C30A89FQ35600095-A977F784-AEDE-40E3-957E-419E7BD6CED2Q35647500-DF4EA0F2-EBAB-4898-A7D6-F4EB6A4C40F6Q35753505-0EFAFF27-5CC4-41CD-BB30-61A116BA02AAQ35760530-4E86F913-1119-43BB-9AAE-1A02CDF464A3Q35794137-A462C410-9600-4AC3-862F-8304D69E94F5Q35976605-9FE2558C-BD7E-45B8-84A3-CB543C5343A0Q36064034-7A1915DE-B7E0-48AF-A6DB-6E7CCEFC7CEBQ36292417-944D7F8A-B53D-468B-9519-659D52F91792Q36362347-EAA7B55E-4EEA-45E0-9C83-EAE54EB9A5D6Q36363268-6223B900-87F1-4414-96C6-7A2AC527D061Q36363861-24755AA0-00D8-4B39-B1F2-B0666615C94C
P2860
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Selective modulation of human ...... ose recombinant interleukin 2.
@ast
Selective modulation of human ...... ose recombinant interleukin 2.
@en
type
label
Selective modulation of human ...... ose recombinant interleukin 2.
@ast
Selective modulation of human ...... ose recombinant interleukin 2.
@en
prefLabel
Selective modulation of human ...... ose recombinant interleukin 2.
@ast
Selective modulation of human ...... ose recombinant interleukin 2.
@en
P2093
P2860
P356
P1476
Selective modulation of human ...... ose recombinant interleukin 2.
@en
P2093
M A Caligiuri
M J Robertson
R J Soiffer
T R Klumpp
P2860
P304
P356
10.1172/JCI116161
P407
P577
1993-01-01T00:00:00Z